rct
    2003

    Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease

    Nakamura S, Hashimoto Y, Mikami M, Yamanaka E, Soma T, Hino M, Azuma A, Kudoh S

    Published in Respirology

    Key Findings

    Four weeks of serrapeptase reduced sputum weight, sputum viscosity and cough frequency in patients with chronic airway disease.

    Conclusions

    Possible mucolytic effect in chronic bronchial disease.

    Limitations

    Small crossover study; single centre; older trial.

    Supplements Studied

    Four weeks of serrapeptase reduced sputum weight, sputum viscosity and cough frequency in patients with chronic airway disease.

    Outcomes Measured

    Immune Function

    Serrapeptase reduced sputum weight, viscosity and cough frequency in chronic airway disease.

    Related Health Concerns

    Cough

    Study Details

    Year:2003
    Sample Size:29
    Duration:4 weeks
    Quality Score:5/10

    Access Study

    View on DOIOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.